ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Neuronetics (NASDAQ:STIM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Valuation & Earnings
This table compares ENDRA Life Sciences and Neuronetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.92) | -0.65 |
| Neuronetics | $149.16 million | 0.59 | -$39.00 million | ($0.54) | -2.35 |
Profitability
This table compares ENDRA Life Sciences and Neuronetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -397.71% | -190.73% |
| Neuronetics | -24.48% | -139.83% | -27.13% |
Insider & Institutional Ownership
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
ENDRA Life Sciences has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ENDRA Life Sciences and Neuronetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Neuronetics | 1 | 0 | 1 | 0 | 2.00 |
ENDRA Life Sciences currently has a consensus price target of $30.00, suggesting a potential upside of 416.35%. Neuronetics has a consensus price target of $3.00, suggesting a potential upside of 136.22%. Given ENDRA Life Sciences’ higher possible upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Neuronetics.
Summary
Neuronetics beats ENDRA Life Sciences on 6 of the 11 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
